The introduction of DRR Dhan 100 (Kamala) and Pusa DST Rice 1, India’s first genome-edited rice varieties, is not merely a tale of scientific ingenuity—it is a litmus test for the nation’s policy, diplomacy, and sovereignty in the biotech age. While the precision gene-editing tools used to create these varieties—CRISPR-Cas9 under SDN1 and SDN2 classifications—have set new benchmarks in crop innovation, the terrain beyond the laboratory is far more complex.
A Liberal Yet Contentious Regulatory Pathway
India has distinguished itself with a progressive regulatory framework that classifies genome-edited crops developed via SDN1 and SDN2 as non-transgenic, exempting them from the stringent biosafety protocols typically applied to GMOs. This policy shift, formalized in March 2022, enabled faster clearance for Kamala and Pusa DST Rice 1 and signaled India’s intent to become an innovation-friendly biotechnology hub.
Yet, this pragmatic regulatory stance has triggered resistance. Groups like the Coalition for a GM-Free India have mounted aggressive campaigns, labelling the deregulation as “unscientific and irresponsible.” Their concerns range from biosafety and ecological impact to seed sovereignty, with critics arguing that the genetic tweaks—regardless of the absence of foreign DNA—still constitute genetic modification. The lack of mandatory labelling, they warn, may erode consumer choice and transparency.
Such debates echo the controversies of Bt cotton and Bt brinjal, underlining India’s historically fraught relationship with genetically engineered crops. Public perception remains clouded by suspicion, and the nuanced distinction between genome editing and genetic modification often fails to resonate with non-expert audiences. As such, effective science communication, stakeholder engagement, and transparency in regulation will be vital to foster public trust and informed policy consensus.
The IPR Conundrum: Sovereignty vs. Dependency
While India celebrates its gene-edited rice success, it does so under the shadow of foreign intellectual property. The CRISPR-Cas9 platform used in the genome editing process is patented, with major global rights held by ERS Genomics, co-founded by CRISPR pioneer Emmanuelle Charpentier. The Indian government now faces the uphill task of negotiating commercial licenses, which could entail prohibitively high royalty fees.
Initially underplayed, the IPR issue is now being addressed by a high-level ICAR committee. Proposals such as a “One Nation, One License” policy—where the government secures a blanket license for national use—have surfaced, but they must navigate a labyrinth of overlapping international patents. This IPR fragility evokes memories of Monsanto’s GM cotton licensing battles, a cautionary tale in losing economic autonomy despite scientific success.
India’s lack of indigenous CRISPR alternatives places its Atmanirbhar Krishi (self-reliant agriculture) vision at risk. Unless domestic research institutions accelerate the development of proprietary gene-editing platforms, India could remain scientifically proficient but commercially dependent—a precarious position in a technology-driven agri-economy.
Agri-Science as Diplomacy: India’s Expanding Global Footprint
Amid these challenges, India is also asserting its agri-science diplomacy. The appointment of Dr. Himanshu Pathak as the first Indian Director General of ICRISAT marks a geopolitical milestone. From leading ICAR to now heading a CGIAR institution headquartered in Hyderabad, Dr. Pathak’s role extends India’s influence over global research agendas, particularly in dryland agriculture and climate resilience.
Under his leadership, ICRISAT has launched the Centre of Excellence for South-South Cooperation in Agriculture (ISSCA)—a knowledge-sharing hub that amplifies India’s contributions to agricultural innovation across Africa, Asia, and Latin America. This reflects a strategic pivot from being a recipient of agri-tech solutions to a provider of low-cost, high-impact technologies for the Global South.
India’s genome-edited rice success—combined with the diplomatic capital it gains through platforms like ISSCA—positions it as a science-driven thought leader in sustainable agriculture. This is not just about seed varieties; it’s about shaping ideologies, trade frameworks, and knowledge ecosystems that define the future of food.
Conclusion: A Tectonic Shift With Fragile Foundations
India’s genome-edited rice rollout is a watershed moment. It holds the promise of higher yields, lower emissions, and better resilience. But the broader story—regulatory leniency under scrutiny, IPR entanglements yet unresolved, and a global leadership role still evolving—reminds us that science, when taken beyond the lab, becomes a deeply political enterprise.
If India is to lead the biotech revolution, it must navigate these layered realities with clarity and courage. Its ability to harmonize scientific advancement, policy foresight, and diplomatic engagement will determine not just the fate of a rice variety—but the shape of its agricultural future.
–Raja Aditya
